Celloram, Inc.
Celloram Inc. is a Cleveland-based biotech startup dedicated to developing innovative medicines for cancer and immune disorders. The company focuses on cellular immunotherapy and small molecule therapeutics, aiming to revolutionize patient care with safer and more effective treatments. With a team of experienced scientists and strategic partnerships, Celloram is advancing its product pipeline towards clinical development and commercialization. The company is also actively engaged in licensing agreements, such as with GENFIT SA, to expand its therapeutic platform into liver disease indications. Celloram's mission is to harness the power of the immune system to create transformative therapies that prevent disease and promote healing, driven by a vision to be a global leader in human health improvement.
Industries
Nr. of Employees
small (1-50)
Celloram, Inc.
Cleveland, Ohio, United States, North America
Products
CLM-022 (inflammasome inhibitor program)
Preclinical small-molecule program targeting NLRP3 inflammasome priming and activation; demonstrated in vitro suppression of IL-1β/IL-18 and pyroptosis in human immune cells and in vivo protection in rodent liver-injury and endotoxemia models following oral and intravenous dosing. The program has been out-licensed to an external development partner for liver disease indications.
NOVS-100 (FABP inhibitor program)
Preclinical small-molecule program focused on inhibition of fatty acid–binding proteins to modulate lipid metabolism and tumor microenvironment biology, intended for oncology and metabolic disease research.
Personalized dendritic cell vaccine workflow (Protexi)
Personalized cancer vaccine workflow that integrates tumor genomic sequencing, computational neoantigen prediction, and ex vivo expanded autologous dendritic cells loaded with patient-specific antigens for immunotherapy development.
CLM-022 (inflammasome inhibitor program)
Preclinical small-molecule program targeting NLRP3 inflammasome priming and activation; demonstrated in vitro suppression of IL-1β/IL-18 and pyroptosis in human immune cells and in vivo protection in rodent liver-injury and endotoxemia models following oral and intravenous dosing. The program has been out-licensed to an external development partner for liver disease indications.
NOVS-100 (FABP inhibitor program)
Preclinical small-molecule program focused on inhibition of fatty acid–binding proteins to modulate lipid metabolism and tumor microenvironment biology, intended for oncology and metabolic disease research.
Personalized dendritic cell vaccine workflow (Protexi)
Personalized cancer vaccine workflow that integrates tumor genomic sequencing, computational neoantigen prediction, and ex vivo expanded autologous dendritic cells loaded with patient-specific antigens for immunotherapy development.
Services
Collaborative medicinal chemistry and compound synthesis
Medicinal chemistry support for design, synthesis, optimization and validation of small-molecule candidates provided to development partners.
Preclinical assay execution and in vivo efficacy testing
Execution of in vitro immunology assays and rodent efficacy studies to generate pharmacology, biomarker and mechanism-of-action data for development candidates.
Neoantigen discovery and computational antigen selection
Tumor genomic sequencing (WES/RNAseq) and computational prediction to identify patient-specific neoantigens and prioritize candidates for vaccine or cell therapy loading.
cGMP antigen production and cell therapy input manufacturing
Production workflows for clinical-grade antigen materials and processed cell therapy inputs under GMP to support early-phase clinical studies.
Tolerogenic dendritic cell development and preclinical testing
Ex vivo induction and characterization of tolerogenic dendritic cells for applications in autoimmunity and transplant, with supporting preclinical efficacy studies.
Partnering, licensing and strategic asset-transition services
Advisory and transactional support to structure licensing deals, joint development agreements, and transfer of early-stage assets to external development partners, including provision of scientific and chemistry support.
Collaborative medicinal chemistry and compound synthesis
Medicinal chemistry support for design, synthesis, optimization and validation of small-molecule candidates provided to development partners.
Preclinical assay execution and in vivo efficacy testing
Execution of in vitro immunology assays and rodent efficacy studies to generate pharmacology, biomarker and mechanism-of-action data for development candidates.
Neoantigen discovery and computational antigen selection
Tumor genomic sequencing (WES/RNAseq) and computational prediction to identify patient-specific neoantigens and prioritize candidates for vaccine or cell therapy loading.
cGMP antigen production and cell therapy input manufacturing
Production workflows for clinical-grade antigen materials and processed cell therapy inputs under GMP to support early-phase clinical studies.
Tolerogenic dendritic cell development and preclinical testing
Ex vivo induction and characterization of tolerogenic dendritic cells for applications in autoimmunity and transplant, with supporting preclinical efficacy studies.
Partnering, licensing and strategic asset-transition services
Advisory and transactional support to structure licensing deals, joint development agreements, and transfer of early-stage assets to external development partners, including provision of scientific and chemistry support.
Expertise Areas
- Small-molecule discovery and medicinal chemistry optimization
- Inflammasome (NLRP3) inhibitor discovery and translational development
- Personalized neoantigen identification and selection using WES/RNAseq
- Autologous dendritic cell manufacturing and antigen loading
Key Technologies
- Whole-exome sequencing (WES)
- RNA sequencing (RNAseq)
- Neoantigen prediction algorithms
- Ex vivo dendritic cell expansion and antigen loading